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Abstract The intrinsic efficacy of orthosteric ligands acting at G-protein-coupled receptors
(GPCRs) reflects their ability to stabilize active receptor states (R*) and is a major determinant of
their physiological effects. Here, we present a direct way to quantify the efficacy of ligands by
measuring the binding of a R*-specific biosensor to purified receptor employing interferometry. As
an example, we use the mu-opioid receptor (m-OR), a prototypic class A GPCR, and its active state
sensor, nanobody-39 (Nb39). We demonstrate that ligands vary in their ability to recruit Nb39 to m-
OR and describe methadone, loperamide, and PZM21 as ligands that support unique R*
conformation(s) of m-OR. We further show that positive allosteric modulators of m-OR promote
formation of R* in addition to enhancing promotion by orthosteric agonists. Finally, we
demonstrate that the technique can be utilized with heterotrimeric G protein. The method is cell-
free, signal transduction-independent and is generally applicable to GPCRs.
DOI: https://doi.org/10.7554/eLife.32499.001
Introduction
The intrinsic efficacy of a ligand acting at a 7-transmembrane (TM) domain, G-protein-coupled
receptor (GPCR) describes its ability to shift the equilibrium from inactive receptor (R) in favor of
active receptor states (R*). Thus, intrinsic efficacy is the parameter that distinguishes agonists, partial
agonists, antagonists, and inverse agonists and is a major determinant of pharmacological activity of
a drug molecule, along with receptor affinity. This is particularly highlighted by the mu-opioid recep-
tor (m-OR), a GPCR responsible for both the pain relieving and unwanted effects of opioid drugs,
such as life-threatening respiratory depression and the rewarding properties that underlie addiction
to drugs such as morphine, oxycodone, and heroin. Even though opioid drugs bind to the same
orthosteric site on m-OR, the physiological outcomes observed are determined by their degree of
intrinsic efficacy and the efficacy requirements of the system (Morgan and Christie, 2011). For
example, the discriminative stimulus of opioid agonists varies depending on efficacy (Walker et al.,
2004), suggesting that opioid agonist efficacy is a determinant of abuse potential. Thus, it has been
shown that higher efficacy ligands have greater addictive liability compared to lower-efficacy opioid
ligands (Center for Substance Abuse Treatment, 2004). In order to be able to predict the ability of
m-OR agonists to cause various physiological effects, an understanding of their intrinsic efficacy is
required.
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Current approaches to determine the intrinsic efficacy of agonists rely upon measurement of sig-
naling downstream of the receptor in tissue- or cell-based systems. In spite of the use of methods to
account for signal amplification which can cause system and measurement bias the calculated intrin-
sic efficacy of ligands can vary based on the species of the tissue or cellular background, ligand bias,
and temporal effects (Kenakin, 2002; Kenakin and Christopoulos, 2011; Luttrell and Kenakin,
2011; Klein Herenbrink et al., 2016). For example, using the same cellular background, the puta-
tively biased opioid ligand TRV130 initiates arrestin recruitment (74% of morphine) downstream of
mouse m-OR, less with human m-OR (14% of morphine), and shows undetectable levels using rat m-
OR (DeWire et al., 2013). Complications such as these make correlations of physiological effects to
values of efficacy and ‘bias factors’ (Rajagopal et al., 2010; Kenakin et al., 2012) difficult to inter-
pret. Therefore, in this study we sought to establish a method to evaluate the intrinsic efficacy of
opioid ligands utilizing a cell-free assay, thereby removing confounds of signaling outputs and signal
amplification.
The recently solved crystal structure of m-OR in complex with the highly efficacious agonist BU72
utilized nanobody 39 (Nb39), a camelid antibody fragment, to stabilize active m-OR (Huang et al.,
2015). Nb39 enhances agonist affinity at m-OR and stabilizes conformational changes in the receptor
associated with a signaling-competent, active-like state, including an outward movement of TM6
(Farrens et al., 1996; Palczewski et al., 2000; Rasmussen et al., 2011b). Nanobodies are small,
monomeric proteins that can be utilized as conformational biosensors and have therefore been used
as tools to monitor formation of active-state b2-adrenergic receptors in live cells (Irannejad et al.,
2013). Consequently, we sought to use Nb39 as a G protein mimic and a probe to detect active-
state conformation of purified monomeric m-OR in reconstituted high density lipoprotein (rHDL) par-
ticles, comprised of the lipids 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine and 1-palmitoyl-2-
oleoyl-sn-glycero-3-phosphoglycerol and Apolipoprotein-A1 (Apo-A1) (Kuszak et al., 2009), using a
variety of orthosteric ligands. We predicted that the intrinsic efficacy of an agonist will determine
the rate of Nb39 binding to m-OR.
We also wished to utilize Nb39 to probe the mechanism by which small molecule positive alloste-
ric modulators (PAMs) alter the activity of orthosteric m-OR ligands. m-PAMS, exemplified by BMS-
986122 (Burford et al., 2013), enhance the affinity and/or efficacy of orthosteric ligands for m-OR,
but show a distinct dependence on which orthosteric ligand is used to probe the allosteric interac-
tion, with the degree of cooperativity being sensitive to the intrinsic efficacy of the orthosteric ligand
(Burford et al., 2013; Livingston and Traynor, 2014). We have suggested that the mechanism of
allosteric enhancement of orthosteric agonist activity involves a disruption of binding of the endoge-
nous negative allosteric modulator Na+, thereby stabilizing an agonist-bound active (R*) state of the
m-OR (Livingston and Traynor, 2014).
In this report, we demonstrate that the rate of Nb39 binding to purified m-OR simulates the action
of heterotrimeric G protein and provides a measure of the intrinsic efficacy of opioid ligands, and
that the efficacy rankings determined using this second messenger- and cell/tissue-independent
assay are significantly correlated with other measures of efficacy. Moreover, we observed differences
in Nb39 dissociation suggestive of ligand-specific R* states. Finally, we show that m-PAMs can alone
promote Nb39 binding, indicating that they stabilize formation of R* to increase the apparent effi-
cacy of partial agonist drugs such as morphine.
Results
Measure of orthosteric agonist efficacy using an interferometry-based
technique
Nb39 enhances the affinity of orthosteric agonists, such as BU72, to bind m-OR (Huang et al., 2015)
by stabilizing active (R*) states of m-OR. Since agonists shift the equilibrium of receptor to R* in pro-
portion to their efficacy to activate downstream signaling, we predicted that agonists should
enhance the binding of Nb39 in an efficacy-dependent manner. To test this hypothesis, we imple-
mented an interferometry-based technique to study the association and dissociation kinetics of
Nb39 binding to m-OR in rHDL. The formation of m-OR containing rHDL was performed using a low
m-OR to rHDL ratio and an ApoAI construct that heavily favors incorporation of m-OR monomers into
rHDL particles (Kuszak et al., 2009). The m-OR-containing rHDL particles were immobilized on an
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interferometry probe, and the probe was then exposed to saturating concentrations of ligands and a
sub-saturating concentration of Nb39 (1 mM) (Figure 1). As shown in Figure 2, there was no detect-
able binding of Nb39 to m-OR in the absence of ligand, indicating a lack of spontaneous formation
of active m-OR, even with Nb39 present. This supports published research indicating low levels of
constitutive activity of m-OR (Divin et al., 2009; Connor and Traynor, 2010).
Figure 1. Cartoon schematic of interferometry assay to detect m-OR:Nb39 interactions. Briefly, (a) Biotin-conjugated rHDL particles containing m-OR are
loaded on streptavidin-coated tips and incubated with saturating ligand (or vehicle) for 10 min. (b) Probe is exposed to Nb39 for five min in the
presence of ligand or vehicle until steady state is reached. (c) In the presence of ligand, probe is moved to well containing no Nb39 to monitor
dissociation for 5 min.
DOI: https://doi.org/10.7554/eLife.32499.002
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Figure 2. Orthosteric ligand-mediated Nb39 association and dissociation in m-OR-rHDL. As described in the
Materials and methods, the association and dissociation of Nb39 (1 mM) was measured using
an OctetRedÒ instrument. Shown is a representative experiment comparing four orthosteric agonists at 30 mM
(a) Using GraphPad Prism 6.02, one-phase association lines were fit and the calculated kobs (b) and koff (c) for each
ligand are plotted (±s.e.m.). Rate constants are means of multiple independent experiments as listed in see
Figure 2 continued on next page
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Conversely, pre-incubation of m-OR with a wide range of agonists of varying structure, both pepti-
des and small molecules, caused binding of Nb39, although to varying degrees (Table 1). In particu-
lar, the presence of a saturating concentration (30 mM) of the high-efficacy agonist BU72
(Neilan et al., 2004; Huang et al., 2015) drove robust and rapid binding of Nb39 (Figure 2,
Table 1). In the presence of the high-efficacy peptide agonist DAMGO, Nb39 bound to m-OR with a
similar rate constant, but DAMGO lead to less overall binding of Nb39 compared to BU72. In con-
trast, pre-incubation with the partial agonist morphine caused slower Nb39 association and less
overall binding of Nb39 relative to BU72 and DAMGO (Figure 2, Table 1), and the rate constant for
Nb39 binding in the presence of the low-efficacy nalbuphine was slower still. Neither of the orthos-
teric antagonists (naloxone or diprenorphine) promoted a m-OR:Nb39 interaction (Table 1).
The above data indicate that the binding of Nb39 is related to agonist efficacy, with
higher efficacy ligands producing an increased Nb39 binding signal and a more rapid association of
Nb39. However, the magnitude of the interference shift is problematic to use as the readout for effi-
cacy since this depends on the initial amount of stable receptor loaded onto the probe which is diffi-
cult to control because of problems of equalizing receptor loads onto the probe, use of different
receptor preparations, plus the fact that is not known how much receptor is actually functional.
Figure 2 continued
Table 1. *Dissociation of Nb39 from the methadone-bound receptor is statistically different from all other ligands
(one-way ANOVA with Tukey’s post-hoc test).
DOI: https://doi.org/10.7554/eLife.32499.003
Table 1. Association and dissociation kinetics of Nb39 to m-OR-rHDL in the presence of various agonists.
kobs and koff were determined for each independent experiment (number of individual experiments indicated in ‘n’ column) and aver-
aged. One-phase association and single-phase exponential decay models were used. Half-time values (t1/2) numbers were calculated
from the respective k values (t1/2 = 0.693/k). A one-way ANOVA was performed followed by a Tukey post-hoc test. Methadone was
found to be statistically different compared to all other orthosteric ligands other than loperamide and PZM21. Both loperamide and
PZM21 were also found to be statistically different from several other ligands, though not as many as methadone.
Ligand kobs ± SEM (min
 1) t1/2ass (sec) koff (min
 1) t1/2dis (sec) N
BU72 0.20 ± 0.01 3.5 0.031 ± 0.001 22 14
DAMGO 0.179 ± 0.008 3.9 0.030 ± 0.001 23 6
Leu-Enk 0.098 ± 0.02 7.1 0.031 ± 0.001 23 9
L-Methadone 0.19 ± 0.02 3.6 0.052 ± 0.003 13 6
Morphine 0.08 ± 0.01 8.5 0.033 ± 0.003 21 7
Nalbuphine 0.023 ± 0.008 30 0.036 ± 0.004 19 11
PZM21 0.064 ± 0.004 11 0.043 ± 0.002 16 6
Endomorphin 2 0.101 ± 0.002 6.9 0.036 ± 0.002 19 6
Loperamide 0.208 ± 0.009 3.2 0.044 ± 0.003 16 6
Oxycodone 0.044 ± 0.001 16 0.028 ± 0.001 25 9
Etorphine 0.180 ± 0.007 3.9 0.026 ± 0.001 27 6
Fentanyl 0.075 ± 0.005 9.2 0.035 ± 0.002 20 6
Met-Enk 0.131 ± 0.004 5.3 0.027 ± 0.001 26 6
Hydrocodone 0.042 ± 0.004 17 0.029 ± 0.001 24 6
Buprenorphine 0.058 ± 0.009 12 0.025 ± 0.001 27 6
Naloxone n/a —— n/a —— 3
Diprenorphine n/a —— n/a —— 3
BMS-986122 0.012 ± 0.001 56 0.027 ± 0.003 25 10
BMS-986187 0.025 ± 0.006 28 0.037 ± 0.005 19 11
DOI: https://doi.org/10.7554/eLife.32499.004
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Consequently, we focused on the association rate constants (Kobs and t1/2). First, we made sure that
agonist binding kinetics was not a confounding factor in measuring Nb39 binding. Opioid ligands
have very fast binding kinetics (Huang et al., 2015) and to confirm equilibrium was reached we used
maximal agonist concentrations and for two distinct ligands, DAMGO and PMZ21 showed these
gave the same results with 10 or 30 min incubation (PZM21 kobs (10 min)=0.060 ± 0.008 min
 1 and
kobs (30 min)=0.064 ± 0.004 min
 1; DAMGO kobs (10 min)=0.15 ± 0.006 min
 1 and kobs (30 min)
=0.16 ± 0.008 min 1). Then, to confirm that the rate constant of Nb39 association to agonist-bound
receptor accurately reflects the intrinsic efficacy of a given agonist, we compared Nb39 association
with four accepted methods of agonist efficacy measurement: (i) maximal ability to activate hetero-
trimeric G protein (Strange, 2008), (ii) intrinsic efficacy as defined by Ehlert’s equation
(Ehlert, 1985), (iii) reduction in agonist affinity in the presence of Na+ ions and GTP (Lee et al.,
1999; Zhen et al., 2015) and (iv) tau (t) as calculated using the Black-Leff operational model
(Black and Leff, 1983). These complimentary methods of agonist efficacy determination generally
agree with one another, but use different measurements of receptor activity to calculate efficacy.
The Nb39 association half-time (t1/2) (Table 1) correlated with the ability of each orthosteric
ligand, when used at a saturating concentration (10 mM), to stimulate G protein activation as mea-
sured by GTPg35S binding (taken from [Livingston and Traynor, 2014]), giving r2 = 0.75, p<0.0001
(Figure 3a). Next, we compared the Nb39 association data with the intrinsic efficacy (e) of the vari-
ous orthosteric ligands, calculated using the Ehlert equation (Ehlert, 1985) with potency and maxi-
mal response obtained from GTPg35S-binding assays and affinity values obtained using radioligand
competition binding (Livingston and Traynor, 2014). There was a statistically significant correlation
between the t1/2 of Nb39 binding and intrinsic efficacy (r
2 = 0.44, p=0.02; Figure 3b). For instance,
etorphine and BU72 are high-efficacy ligands with equivalent e values (4.7) and pre-incubating m-OR
with either ligand results in a similar Nb39 association half-time (t1/2 = 3.5 sec for BU72, 3.9 sec for
etorphine). In this case, the correlation was weaker than the comparison between Nb39 association
and GTPg35S maximum stimulation, and we excluded data collected with nalbuphine, as a potency
value could not be determined due to its weak activation of G protein in our system.
Determination of efficacy can vary based on signaling output chosen, especially in the case of
bias where ligands may preferentially activate certain pathways over others. To avoid the use of a
signaling measure, that is G-protein activation or b-arrestin recruitment, we examined the shift in
agonist affinity in response to the presence of Na+ ions and GTP, using GTPgS. It is known that addi-
tion of Na+ ions and guanine nucleotide decreases the affinity of agonists to bind m-OR and that the
degree of shift is larger for higher efficacy ligands (Lee et al., 1999). Using our previously published
data (Livingston and Traynor, 2014), we plotted the shift in affinity of the orthosteric ligands by the
addition of NaCl/GTPgS (100 mM and 10 mM, respectively) versus the calculated t1/2 of Nb39 associ-
ation to ligand-bound m-OR, from Table 1. This correlation was significant (Figure 3c, r2 = 0.73,
p=0.002), although BU72 and etorphine had to be excluded from the analysis due to their paradoxi-
cal lack of a Na+/GTPgS shift (Lee et al., 1999). Finally, using the Black-Leff operational model
(Black and Leff, 1983), the intrinsic efficacy (t) was calculated using our published data from the
[35S] GTPgS assay (Livingston and Traynor, 2014). This variable can only be reliably calculated and
separated from functional affinity (KA) for partial agonists (Figure 3d). Using this limited dataset (Fig-
ure 3—source data 1), we observed a significant correlation (r2 = 0.83) between t and the t1/2 of
Nb39 association.
The above efficacy comparisons are all related to receptor-G-protein interactions. However, as
mentioned above the m-OR, like other GPCRs, may show a signaling bias in that ligands could pref-
erentially activate G proteins or b-arrestin-mediated downstream signaling, this has been demon-
strated for example with the newer ligands PZM21(Manglik et al., 2016) and TRV130
(DeWire et al., 2013). To determine if there was a correlation with b-arrestin recruitment, we com-
pared published data of t values for a series of eight opioid ligands (McPherson et al., 2010) with
their Nb39 association rates from Table 1. For this dataset there was a significant correlation, albeit
weaker (r2 = 0.62, p=0.019; Figure 3e).
In addition to monitoring Nb39 association, the interferometry technique also allows for measure-
ment of the dissociation of Nb39 from ligand-bound m-OR (Figures 1 and 2). Compared to the wide
range of association rates observed, the dissociation of Nb39 was generally constant across the vari-
ous ligands, including full and partial agonists and compounds such as buprenorphine that have
slower receptor dissociation (Table 1). As examples, the Nb39 dissociation rate (t1/2) was the same
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Figure 3. Correlation of association times of Nb39 with various measures of agonist efficacy. The t1/2 of association of Nb39 in the presence of
saturating agonist was measured and is plotted against (a) maximal stimulation of GTPg35S binding by agonist, (b) the calculated Ehlert efficacy
(Ehlert, 1985) values for each agonist to activate G protein, (c) the shift in affinity of the agonist as measured by radioligand competition binding in the
absence or presence of Na+/Guanine nucleotide, and (d) the t value using data from GTPg35S assays (Livingston and Traynor, 2014) or (e) b-arrestin
recruitment assays; McPherson et al., 2010), analyzed with the Black-Leff operational model (Black and Leff, 1983). Data used to compile correlation
graphs is listed in the source data table. The ligands are: (1) BU72, (2) DAMGO, (3) Leu-Enk, (4) L-methadone, (5) Morphine, (6) Nalbuphine, (7)
Endomorphin 2, (8) Loperamide, (9) Oxycodone, (10) Etorphine, (11) Fentanyl, (12) Met-Enk, (13) Hydrocodone, (14) Buprenorphine, (15)
Morphine + BMS-986122, (16) Morphine + BMS-986187. Correlation analysis was performed using GraphPad Prism 6.02.
DOI: https://doi.org/10.7554/eLife.32499.005
The following source data is available for figure 3:
Source data 1. List of values used to construct correlation graphs.
DOI: https://doi.org/10.7554/eLife.32499.006
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from both morphine-bound m-OR (0.033 min 1), the BU72-bound m-OR (0.031 min 1) and buprenor-
phine bound m-OR (0.025 min 1), despite the markedly different efficacies of these agonists. This
may suggest that both full and partial agonists are capable of producing similar active states,
although to different extents as indicated by the observed association rates, or that Nb39 is incapa-
ble of differentiating partial agonist from full agonist states. Unexpectedly, Nb39 dissociated more
rapidly from L-methadone- and loperamide-bound m-OR, with rates of 0.052 ± 0.003 min 1 and
0.044 ± 0.003 min 1 for L-methadone and loperamide, respectively (Figure 2c; Table 1). This differ-
ence can be interpreted as a distinct methadone-and loperamide-bound m-OR conformation(s) with
decreased affinity for Nb39 as compared to other ligands. To further explore this possibility, we uti-
lized the biased opioid agonist PZM21(Manglik et al., 2016). The presence of PZM21 resulted in
Nb39 recruitment and afforded dissociation kinetics (Table 1) similar to those of methadone, provid-
ing further evidence that different ligands may cause the receptor to interact with Nb39 in unique
ways.
To ensure that Kobs provides a viable surrogate for Nb39 interaction with m-OR, we experimen-
tally determined the true Kon, Koff, and Kd of Nb39 for particular agonists (Figure 4). The agonists
chosen included the highly efficacious BU72 and DAMGO, the partial agonist morphine, and metha-
done which showed atypical dissociation. The ligands displayed differences in their ability to pro-
duce binding of increasing concentrations of Nb39. In addition, the Koff values given in the figure
legend were similar to those shown in Table 1, with methadone as an outlier in both cases. The affin-
ity of Nb39 for m-OR varied for each ligand such that the calculated Kon values followed the same
pattern as Kobs, namely BU72 > DAMGO > methadone > morphine. From these data, it can be seen
that Kobs is a suitable parameter for efficacy determination.
Figure 4. Association and dissociation of a range of Nb39 concentrations induced by various agonists. The association of six different concentrations of
Nb39 was measured in the presence of saturating ligand concentrations. Utilizing global regression analysis, the Kd of Nb39 (nM) for ligand bound
receptor was calculated as follows: BU72 (144 ± 4), DAMGO (194 ± 9), Morphine (944 ± 13), Methadone (580 ± 3). The Kon values (min
 1, M 1  10 5)
were BU72 (2.35 ± 0.45), DAMGO (17.8 ± 0.5), Morphine (0.43 ± 0.05), and Methadone (1.21 ± 0.07) and the Koff values (min
 1) BU72 (0.034 ± 0.0003),
DAMGO (0.034 ± 0.003), morphine (0.04 ± 0.003), methadone (0.07 ± 0.0002).
DOI: https://doi.org/10.7554/eLife.32499.007
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Allosteric modulation of m-OR in rHDL by small-molecule PAMs
Previously, we have suggested that the m-PAM, BMS-986122, enhances the affinity and efficacy of
orthosteric ligands by stabilizing active state(s) of m-OR. To test this hypothesis using the binding of
Nb39 to m-OR, we first needed to validate that BMS-986122 had detectible allosteric activity at
monomeric m-OR in rHDL particles, as all previous data on the compound were generated using cell
membrane preparations. The affinity of L-methadone for monomeric m-OR determined from compe-
tition binding experiments using the opioid antagonist 3H-diprenorphine (DPN) in the presence or
absence of 10 mM BMS-986122 was enhanced three-fold in the presence of 10 mM BMS-986122 (Fig-
ure 5). This shift is much smaller than seen in membranes prepared from C6 rat glioma cells stably
expressing MOPr (Burford et al., 2013). In order to determine if this diminished BMS-986122 activ-
ity in the m-OR-rHDL system was a property of BMS-986122 or a property of purified m-OR, we inves-
tigated BMS-986187, another PAM that is structurally distinct from BMS-986122 (Figure 5).
Although initially discovered as a PAM of the closely related delta opioid receptor (d-OR), this com-
pound is a weak PAM at the m-OR (Burford et al., 2015). In contrast to BMS-986122, BMS-986187
produced a 12-fold enhancement of L-methadone affinity for m-OR in the rHDL system (from a
Ki = 2696 (1970–3691) nM to 212 (142-317) nM), and shifted the affinity of DAMGO by 6-fold (from
a Ki of 1240 (632–2438) nM to 212 (142-317) nM), although it failed to alter the affinity of morphine,
(Ki = 630 nM in the absence and 500 nM in the presence of BMS-986197 (Figure 5). This probe
dependence matches that seen with BMS-986122 in cell membranes, and can be most simply
explained by a two-state model of GPCR function (Monod et al., 1965; Livingston and Traynor,
2014) in which the m-PAMs stabilize R* states of m-OR. We performed competition assays with
L-methadone in the presence of increasing concentrations of BMS-986187 and applied the allosteric
ternary complex model (GraphPad Prism) to calculate a cooperativity factor (a) of 58 and a KB of 4.5
mM, representing the affinity of BMS-986187 for the unoccupied m-OR in rHDL. This is similar to data
obtained for BMS-986187 at the m-OR in cloned membranes (KB of 5.5 mM, log ab of 1.16;
Livingston et al., 2018) determined from a [35S]GTPgS functional assay using a derivation of the
allosteric ternary complex model (Leach et al., 2010). From these values, we determined the affinity
of BMS-986187 for the methadone-bound m-OR in rHDL (KB/a) to be 77 nM. This represents an
increase of 58-fold in the affinity of the modulator in the presence of methadone, indicating a strong
preference for the active R* state of the receptor.
We hypothesized that both PAMs stabilize active R* states of m-OR but that BMS-986187 has an
increased allosteric interaction with m-opioid agonists compared to BMS-986122, as seen by the
enhanced cooperativity with m-opioid agonists in competition binding assays and in our previous
functional and binding assays using cell membranes (Livingston et al., 2018). Therefore, we pre-
dicted that the allosteric ligands alone should promote the binding of Nb39, but that Nb39 binding
in the presence of BMS-986187 would be more rapid and to a greater extent than in the presence of
BMS-986122. Indeed, both allosteric ligands were able to cause Nb39 binding, although at a slower
rate as compared to most orthosteric agonists (Figure 6a; Table 1). However, dissociation of Nb39
from the BMS-986122-bound or BMS-986187-bound m-OR proceeded with a koff similar to Nb39 dis-
sociation from m-OR bound to orthosteric agonists (other than methadone, loperamide and PMZ21).
This suggests that the active states of m-OR stabilized by the PAMs may be similar to those stabilized
by traditional orthosteric agonists, although different from those stabilized by L-methadone and
PMZ21.
In addition to the ability of the PAMs to stabilize R* conformations of m-OR alone, we were inter-
ested in investigating the cooperative effects of the allosteric ligands on the ability of orthosteric
agonists to promote Nb39 binding. Since both allosteric ligands have the ability to increase the effi-
cacy of various orthosteric ligands in cell-based signaling assays (Livingston and Traynor, 2014;
Burford et al., 2015), we expected that this increase in efficacy would manifest as an increase in the
observed association rate constant of Nb39, and that BMS-986187 would have a larger effect than
BMS-986122. Shown in Figure 6b is the ability of the two m-PAMs to enhance morphine-driven
recruitment of Nb39. As predicted, both allosteric ligands enhanced the rate constant of Nb39 asso-
ciation. Using the association rates in the presence of modulator and data from cell-based GTPg35S-
binding assays of morphine in the presence of the modulators, the t values were plotted in
Figure 3e. These agreed with the correlation, indicating the increase in association was accompa-
nied by an increase in intrinsic efficacy.
Livingston et al. eLife 2018;7:e32499. DOI: https://doi.org/10.7554/eLife.32499 9 of 23
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We repeated the same experiment with the orthosteric ligands L-methadone and DAMGO, but
used a lower concentration of Nb39 (100 nM) to enhance sensitivity as these orthosteric ligands are
of higher efficacy. Both PAMs enhanced the rate constant of DAMGO-driven Nb39 binding (Table 2)
and slowed the dissociation of Nb39 from m-OR, with BMS-986187 having a larger effect. Unexpect-
edly, the association of Nb39 to L-methadone-bound m-OR was slowed in the presence of either
Figure 5. Allosteric modulation of m-OR-rHDL by small molecule PAMs. Structures of (a) BMS-986187 and (b) BMS-986122. The ability of BMS-986122 (c)
or BMS-986187 (d) to enhance the binding affinity of L-methadone was measured using displacement of the orthosteric antagonist 3H-diprenorphine.
The dotted line in (c) shows the effect previously obtained in membranes from C6m cells (Livingston and Traynor, 2014). The effect of BMS-986187 on
L-methadone affinity is plotted in (e). Enhancement of the affinity of DAMGO or morphine in the presence of 10 mM BMS-986122 is shown in (f) and (g),
respectively. All plotted points are means ±s.e.m. of three (morphine) or five independent experiments (all other), each in duplicate. Nonlinear
regression analysis with GraphPad Prism 6.02 was utilized to determine the affinity of the ligands. Hill slopes were not significantly different from unity.
DOI: https://doi.org/10.7554/eLife.32499.008
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BMS-986122 or BMS-986187. Additionally, the dissociation of Nb39 was unchanged by BMS-986122
but slowed significantly by BMS-986187 (Table 2).
Finally, we sought to determine if we could use purified heterotrimeric G protein binding to m-OR
in place of the Nb39 biosensor. In order to allow for measures of association and dissociation, solu-
ble heterotrimeric G protein composed of a complex of myristoylated Gai1, b1, and the g2 C68S
mutant lacking prenylation was utilized (see Materials and methods). For this experiment, we studied
BU72 and morphine as two ligands with differing efficacy. Each ligand was able to promote binding
of 100 nM heterotrimeric G protein to m-OR, though to different extents and there was low binding
in the absence of ligand (Figure 7a). Utilizing a global fit of the data, the Kd for G protein varied
between ligands (see legend to Figure 7). In contrast to Nb39 which dissociated very rapidly, the
dissociation t1/2 of G protein was much slower in the presence of BU72 (231 min) or morphine (182
min). To test the hypothesis that this slow dissociation was due to formation of highly stable nucleo-
tide-free receptor:G protein complexes (Rasmussen et al., 2011b), dissociation was measured in
Figure 6. Effects of allosteric ligands on binding kinetics of Nb39. The association and dissociation of Nb39 (1 mM)
was measured as described in the Materials and methods. (a) Shown is a representative experiment of data in
Table 1, comparing two allosteric agonists at 30 mM. (b) Representative experiment comparing the kinetics of
Nb39 binding in the presence of morphine in the absence (black), or presence of 30 mM BMS-986122 (green), or
30 mM BMS-986187 (blue).
DOI: https://doi.org/10.7554/eLife.32499.009
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the presence of 1 mM GDP. The presence of the nucleotide rapidly enhanced G protein dissociation
(Figure 7b).
Discussion
We have described a method for examining the efficacy of orthosteric and allosteric ligands of a pro-
totypic class A GPCR, m-OR, which relies upon the ability of the conformationally-selective sensor
Nb39 to recognize active (R*) state(s) of the receptor as confirmed using heterotrimeric G protein.
Understanding the effects of ligands on the distribution of receptor conformations is crucial in pre-
dicting their activity at downstream signaling outputs and in vivo. Direct measurement of Nb39 bind-
ing to m-OR using interferometry is independent of signaling and does not require calculations of
efficacy from parameters determined in signaling assays. Further, the output of the interferometry
assay is not subject to amplification and is dependent only upon receptor-ligand interaction,
enabling detection of fine distinctions in agonist action that may be masked when measuring a
downstream signaling output (Black and Leff, 1983; Ehlert, 1985). Importantly, the technique has
the potential to detect differences in agonist-induced receptor conformations that may predict
biased signaling without relying upon traditional calculations of ‘bias factors’ (Kenakin et al., 2012;
Stott et al., 2016). Finally, the method can be applied to positive allosteric modulation of orthos-
teric ligands and provides insight into the mechanism of action of PAMs at m-OR by showing these
molecules, although acting at a distinct site, stabilize active (R*) receptor states even in the absence
of orthosteric agonist. Overall, the method provides a way of quantitatively examining the efficacy
of m-OR orthosteric and allosteric ligands to stabilize R*, and can readily be applied to other GPCRs
with conformationally-selective nanobodies available (Staus et al., 2014; 2016).
As predicted based on data from previous studies with nanobodies (Rasmussen et al., 2011a;
Irannejad et al., 2013; Huang et al., 2015), orthosteric agonists resulted in robust Nb39 binding,
while the orthosteric antagonists naloxone or diprenorphine failed to promote detectable Nb39
binding. We show the ability of an agonist to promote Nb39 binding is correlated with its ability to
promote signal transduction through Gi/o protein as measured by GTPg
35S binding. In fact,
Table 2. Alteration in Nb39 kinetics in the presence of m-PAMs
Morphine (1 mM Nb39)
kobs (min
 1) t1/2Assoc (sec) koff (min
 1) t1/2Diss(sec) N
Vehicle 0.08 ± 0.01 8.5 0.033 ± 0.001 21 3
BMS-986122 0.11 ± 0.001 6.4 0.032 ± 0.0002 22 3
BMS-986187 0.13 ± 0.01 *** 5.3 0.024 ± 0.0004 29 3
L-Methadone (100 nM Nb39)
kobs (min
 1) t1/2Assoc (sec) koff (min
 1) t1/2Diss(sec) n
Vehicle 0.087 ± 0.009 8.0 0.050 ± 0.004 † 14 7
BMS-986122 0.077 ± 0.007 9.0 0.047 ± 0.004 ++ 15 7
BMS-986187 0.055 ± 0.004 * 13 0.033 ± 0.002 ** 21 7
DAMGO (100 nM Nb39)
kobs (min
 1) t1/2Assoc (sec) koff (min
 1) t1/2Diss(sec) n
Vehicle 0.051 ± 0.003 14 0.035 ± 0.003 ‡ 20 7
BMS-986122 0.050 ± 0.01 13 0.029 ± 0.003 24 7
BMS-986187 0.050 ± 0.004 14 0.022 ± 0.001* 31 7
Values are means from independent experiments (number of individual experiments indicated in ‘n’ column). Analyses were performed by two-way
ANOVA with a Tukey post-hoc test.
*Indicates significance compared to vehicle condition for each orthosteric ligand (*p<0.05, **p<0.01, ***p<0.001). ++Indicates p<0.01 as compared to
L-methadone/BMS-986187 combination.
†Indicates p<0.01 as compared to morphine/vehicle combination.
‡Indicates p<0.01 as compared to DAMGO/vehicle combination.
DOI: https://doi.org/10.7554/eLife.32499.010
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measurement of Nb39 binding is more sensitive than GTPg35S binding, as some low-efficacy ligands,
including nalbuphine and the m-OR PAMs, were able to promote Nb39 binding but failed to show
measurable G protein activity using the GTPg35S-binding assay (Livingston and Traynor, 2014).
While theoretically measuring the same process, that is m-OR active-state promotion by agonists,
leading to a protein-protein interaction at the receptor’s cytoplasmic face, the output of the
GTPg35S assay can vary dramatically based upon nucleotide concentration, receptor:Gi/o protein
ratios, MgCl2 concentration, NaCl concentrations, time, and temperature (Traynor and Nahorski,
1995; Szekeres and Traynor, 1997; Remmers et al., 2000; Heusler et al., 2016). In comparison,
Nb39 binding is not an enzymatic process like nucleotide exchange, but instead represents a
Figure 7. Association and dissociation of heterotrimeric G protein and the effect of GDP on dissociation. (a) Utilizing a global fit analysis the affinity (Kd)
of G protein for m-receptor was determined as 13 ± 1 nM for the BU72-bound receptor and 2.9 ± 0.8 nM for the morphine-bound receptor, though
these are pseudo-affinity constants as the G protein binding was nearly irreversible on the time-scale studied. Only in the presence of nucleotide (b) did
the BU72-bound heterotrimer rapidly dissociate.
DOI: https://doi.org/10.7554/eLife.32499.011
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bimolecular binding event. However, it is recognized that measured efficacy in a cellular context will
depend on the signal measured and the environment of the receptor.
It is important to note that the fact we see differences in Kobs for the various agonists indicates
that each agonist stabilizes a different distribution of active states of m-OR, but that these states are
all recognized by Nb39. The range of active m-OR conformations formed by the orthosteric agonists
and/or allosteric modulators recognized by Nb39 is, as of yet, unknown, and within a cellular context
will depend on the environment and state of the receptor, but the crystal structure of active m-OR
bound to Nb39 shows that the nanobody does stabilize an active state of the receptor displaying
the prototypic outward movement of TM6 associated with activation of GPCRs (Farrens et al.,
1996; Scheerer et al., 2008; Rasmussen et al., 2011b; Kruse et al., 2013; Huang et al., 2015).
Also, the affinities of the agonist BU72 for Nb39-bound m-OR and Gai-bound m-OR are similar
(Huang et al., 2015), suggesting the conformations of m-OR stabilized by Nb39 and Gai are also
comparable, a finding confirmed by our current data with heterotrimeric G protein. The correlation
with other efficacy measures leaves room for interpretation on the nature of receptor states that
Nb39 can bind. If Nb39 was able to recognize and bind all active-like conformations capable of initi-
ating downstream signal transduction, one might expect perfect correlations with other measures of
efficacy. As evidenced, the correlation with Ehlert’s efficacy values shows this is not the case.
Although a well-accepted method for determining intrinsic efficacy, Ehlert’s measure relies upon
data collected from a signaling assay, therefore if a ligand has a signaling bias, the results may differ
depending on which signaling output is chosen. The Ehlert equation relies upon a potency value
(EC50), affinity value, and an Emax that is relative to a chosen standard. The EC50 of an assay will be
heavily reliant on the system: receptor reserve, time of incubation, and inherent system maximum
and is therefore not an absolute number (Strange, 2008). Additionally, the affinity of the ligand is
not a factor in the interferometry assay as all ligands are present at saturating concentrations. This is
likely why the correlation with t as calculated from the operational model is stronger (Figure 4). By
calculating t alone, ligand affinity is removed as a descriptor of efficacy.
Data from the interferometry experiments correlated strongly with the shift in affinity of orthos-
teric agonists in the presence of Na+ ions and Guanine nucleotides. Affinity is ideally system-inde-
pendent and so the Na+/GTPgS shift appears to be more reflective of true intrinsic efficacy, or ability
of a ligand to discriminate between R and R*, with no dependence on the selection and measure-
ment of a signaling output. It should be noted that two agonists, etorphine and BU72, are unique in
that they exhibit little sensitivity to Na+/GTPgS despite their high efficacy. It is possible that their
insensitivity to Na+ ions is not absolute. Rather, etorphine and BU72 may be extremely negatively
cooperative with Na+ binding, thereby reducing the potency of Na+ to alter the affinity of these
ligands to such a degree that no shift was observed at the Na+ concentration tested (100 mM).
Nonetheless, the lack of the ability of Na+/GTPgS to alter affinity of etorphine and BU72 is in agree-
ment with the lack of allosteric effects of the PAMs on these ligands (Livingston and Traynor,
2014), suggesting they drive formation of R* too efficiently to be further enhanced by allosteric
ligands. Indeed, NMR data have suggested that BU72 is a ‘superagonist’ capable of stabilizing con-
formational changes in m-OR, in particular increased dynamics in intracellular loop 1 and helix 8, that
are not seen with other full agonists (Sounier et al., 2015). Etorphine may act in a similar fashion.
The rationale of the present study was to directly compare agonist ability to generate an active
conformation of the m-OR as a determinant of intrinsic efficacy without the need to measure a down-
stream signal. The comparative measures above are all indicative of Ga function. However, if meas-
ures are taken downstream that involve the Gbg subunit then the actual value of the efficacy
measure might vary but the rank order should stay the same since Nb39 mimics the action of hetero-
trimeric G proteins. It is possible that non-G-protein-mediated actions, that could include b-arrestin
recruitment, would show a different rank order. Consequently, we also compared the kinetics of
Nb39 binding induced by several agonists with published agonist efficacy data for b-arrestin recruit-
ment (McPherson et al., 2010) and saw a significant correlation suggesting that Nb39 may recog-
nize m-OR states that recruit b-arrestin as well as those that recruit G protein, or that recruitment of
b-arrestin to m-OR must be preceded by transition to a Nb39-recognizable state. We did not neces-
sarily expect this finding given that nanobodies which promote high affinity agonist binding of the
b2AR recognize a conformation of the receptor similar to the conformation which binds G protein
(Rasmussen et al., 2011a). On the other hand the result does support the finding that some ligands,
including the biased agonist PZM21, show different kinetics. It will be important in the future to
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develop the system to follow b-arrestin recruitment to purified m-OR directly. However, this will
require the purification of homogenous, phosphorylated receptor.
Like the orthosteric agonists, the allosteric ligands BMS-986122 and BMS-986187 also drove
Nb39 binding to m-OR suggesting they can directly activate the receptor to form R*, even in the
absence of an agonist occupying the orthosteric site. However, the rate and extent of Nb39 binding
produced by the PAMs was low, comparable to low-efficacy orthosteric agonists such as nalbuphine.
Compared to BMS-986122, BMS-986187 promoted Nb39 binding to a greater extent and at a faster
rate, in line with its higher activity to enhance orthosteric ligand binding affinity to m-OR in rHDL par-
ticles. The fact that BMS986187 is able to recruit Nb39, albeit to a much smaller extent than orthos-
teric agonists, identifies this compound as an ago-PAM, a compound that can activate receptor in
the absence of orthosteric agonist and demonstrates the high sensitivity of the assay. This is sup-
ported by our recent observation that BMS986187 acts as an agonist in the adenylate cyclase assay
but not in an assay for G-protein activation of b-arrestin recruitment (Livingston et al., 2018). Our
proposed mechanism for PAMs at the m-OR is to allosterically modulate the Na + ion binding site
and therefore drive or help to drive a active conformational (R*) ensembles. Thus, there is a fine line
between a PAM and an ago-PAM that predicts a continuum between compounds that are silent
(SAMs) and bind to the allosteric site without any obvious activity, PAMs that promote agonist action
and ago-PAMs. Moreover, these definitions will depend on the efficacy requirements of the system.
When added together with orthosteric ligands the PAM, BMS-986187, increased the association
rate of Nb39 to m-OR induced by morphine, but did not alter the rate of Nb39 binding in the pres-
ence of DAMGO and decreased the effect of association rate in the presence of methadone. In pre-
vious studies, we showed the efficacy of the partial agonist morphine, determined using Ehlert’s
equation, was increased two-fold by BMS-986122 (from e = 0.5 to e = 1.0), whereas the efficacy of
DAMGO (e = 2.0 versus 2.1) was essentially unchanged in the presence of BMS-986122 and L-meth-
adone was slightly decreased (from e = 1.1 to 0.9). Instead with L-methadone and DAMGO there is
an increase in potency. Crystallographic work is underway to determine the mode of PAM binding
and to determine the structural features that govern allosteric modulation of m-OR.
In addition to association rate constants, valuable information can be obtained from the rates of
Nb39 dissociation since we can assume this rate is a product of the affinity of Nb39 for agonist-
bound and active m-OR. The dissociation rate of Nb39 was equal in the presence of most orthosteric
and the allosteric ligands examined in this study, arguing that Nb39 recognizes all active (R*) confor-
mations equally and/or that both full and partial orthosteric agonists, as well as the allosteric modu-
lators, stabilize a common ensemble of m-OR active conformations that is recognized by Nb39.
These arguments are consistent with the exception of L-methadone, loperamide and PZM21 which
show faster Nb39 dissociation. This indicates that the receptor has decreased affinity for Nb39 in the
presence of these ligands, possibly reflecting a unique set of receptor conformations. In support of a
differential binding mode for L-methadone, this ligand is the most sensitive orthosteric agonist
toward allosteric modulation with three different chemical scaffolds (BMS-986122, BMS-986187, and
MS1 [Bisignano et al., 2015]), and in turn greatly enhances the affinity of BMS-986187 for the allo-
steric site. This suggests that L-methadone, and possibly PZM21 and loperamide, could engage with
m-OR in distinct ways, generating unique conformational ensembles that can be seen in its effects on
the binding characteristics of both Nb39 and small-molecule allosteric modulators. It is possible that
other factors, including differential rates of ligand dissociation could be confounding factors in Nb39
dissociation, but the fact that these differences are only seen for three ligands would argue against
this. Although we have tested a number of structurally diverse m-OR orthosteric ligands, and both
full and partial agonists, it is feasible that each ligand generates distinct active conformations that
are indistinguishable to Nb39, including as discussed above the possibility of b-arrestin preferring
conformations. This is likely given evidence at the b2-adrenergic (Yao et al., 2006) and b1-adrener-
gic receptors (Warne et al., 2011) suggests partial agonist conformations differ from full agonist-
bound conformations. Thus, it should be possible to develop selective nanobodies that recognize
agonist-specific m-OR* states. If true it is feasible that these different conformational states may con-
tribute to the lower levels of cross-tolerance observed with methadone compared to other opioids
in animal models (Neil, 1982; Posa et al., 2016), and the higher relative potency values for metha-
done than expected during opioid rotation in patients (Knotkova et al., 2009). Moreover, these dif-
ferent receptor states could explain the reported biased agonist nature of PMZ21(Manglik et al.,
2016). However, this represents the most basic piece of the puzzle and in the whole cell many
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factors not present in rHDL particles, such as differential posttranslational processing of the recep-
tor, and the presence of accessory proteins, as well as different membrane lipids could contribute to
the ensemble of receptor conformations obtained.
The affinity of Nb39 for m-OR (Huang et al., 2015) is low compared to Nb80 at the b2AR
(Manglik et al., 2016). Thus, Nb39 does not bind receptor in the absence of agonist and so does
not create agonist conformations of the receptor or force orthosteric agonist to bind to these unique
conformations. Although it is possible that the agonist bound Nb39 conformation in the presence of
Nb 39 could be different from the agonist and heterotrimerc G-protein-bound conformations, our
findings using a mutated, soluble form of heterotrimeric G protein confirmed the biological rele-
vance of our model system by demonstrating that Nb39 is a suitable surrogate for heterotrimeric G
proteins which are the native ‘active-state sensors’ of R* states of GPCRs. However, for these assays
protein tools such as nanobodies are preferred due to the challenges associated with using G-pro-
tein complexes made up of three subunits. These include selection of subunits, which themselves
could cause differences in receptor binding (Remmers et al., 2000), inclusion or exclusion of nucleo-
tide, selection and concentration of nucleotide, and nonspecific binding. Indeed, some native Ga
subtypes and wild-type Gg cannot be used as obligatory lipid groups (palmitoylation, geranyl-gera-
nylation) require detergents which would disrupt the rHDL particles, and also could drive direct
lipid-lipid association with the rHDL particles. This creates the possibility for multiphase association
and dissociation kinetics which can make data analysis difficult, for example the Kd value may be an
amalgamation of two distinct values derived from binding of G protein to receptor and to the rHDL
discs. Moreover, heterotrimeric G-protein binding is not simply a bimolecular interaction between G
protein and receptor but an enzymatic process in which nucleotide can dramatically influence rates
and extents of binding. The extremely slow dissociation of heterotrimeric G protein makes the Kd
calculated a ‘pseudo’ rate constant as the reaction is irreversible on the time scale of the assay in the
absence of nucleotide.
In summary, we have described a novel method for the quantitative evaluation of efficacy of both
orthosteric and allosteric ligands using purified m-OR in rHDL particles. This biophysical technique is
also able to identify ligands, in particular L-methadone and PZM21, that induce distinct conforma-
tions of m-OR. Allosteric modulators of m-OR are themselves capable of generating active conforma-
tions of m-OR competent to bind Nb39 and of driving G-protein-independent high-affinity agonist
binding. This technique is more sensitive than traditional measures of efficacy and is not reliant upon
signal amplification. The methodology should be applicable to a wide variety of GPCRs.
Materials and methods
Key resources table
Reagent type
(species) or
resource Designation Source or reference Identifiers Additional information
Peptide,
recombinant protein
mu-opioid receptor Manglik et al. (2012) OPRM1
Peptide,
recombinant protein
Gbetagamma In˜iguez-Lluhi et al., 1992
Peptide,
recombinant protein
Myristoylated Gai1 Greentree and Linder, 2004
Peptide,
recombinant protein
Apolipoprotein-AI Kuszak et al., 2009
Peptide,
recombinant protein
[D-Ala2, N-Me-Phe4,
Gly5-ol]-Enkephalin
acetate salt
(DAMGO)
Sigma E7384 CAS#100929-53-1
Peptide,
recombinant protein
Leu-Enkephalin Sigma L9133
Peptide,
recombinant protein
Met-Enkephalin Sigma M6638 CAS#82362-17-2
Continued on next page
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Continued
Reagent type
(species) or
resource Designation Source or reference Identifiers Additional information
Peptide,
recombinant protein
Endomorphin 2 Sigma SCP0133
Peptide,
recombinant protein
Nanobody 39 (Nb39) Huang et al., 2015
Chemical
compound, drug
3H-diprenorphine Perkin Elmer NET1121250UC
Chemical
compound, drug
Morphine sulfate National Institute on Drug
Abuse, NIH. Drug Supply
Catalog
9300–001 CAS # 6211-15-0
Chemical
compound, drug
(R)-Methadone National Institute on Drug
Abuse, NIH. Drug Supply
Catalog
9250–005 CAS# 125-58-6
Chemical
compound, drug
Buprenorphine National Institute on Drug
Abuse, NIH. Drug Supply
Catalog
9064–110 CAS# 53152-21-9
Chemical
compound, drug
BU72 Huang et al. (2015)
Chemical
compound, drug
Diprenorphine Other CAS# 14357-78-9:
Opioid Research Center,
U Michigan
Chemical
compound, drug
Etorphine Other CAS# 14521-96-1: Opioid
Research Center,
U Michigan
Chemical
compound, drug
Fentanyl National Institute on Drug
Abuse, NIH. Drug Supply Catalog
9801–001 CAS# 1443-54-5
Chemical
compound, drug
Hydrocodone Other CAS# 125-29-1:Opioid
Research Center,
U Michigan
Chemical
compound, drug
Loperamide Other CAS # 34552-83-5: Opioid
Research Center,
U Michigan
Chemical
compound, drug
Nalbuphine Other CAS# 23277-43-2: Opioid
Research Center,
U Michigan
Chemical
compound, drug
Naloxone Sigma PHR1802 CAS# 51481-60-8
Chemical
compound, drug
Oxycodone Other CAS# 76-42-6: Opioid
Research Center,
U Michigan
Chemical
compound, drug
PZM21 Manglik et al. (2016)
Chemical
compound, drug
BMS-986187 Bristol Myers Squib; Burford et al. (2015) CAS# 684238-37-7
Chemical
compound, drug
BMS-986122 Bristol Myers Squib; Burford et al. (2013) CAS# 313669-88-4
Software,
algorithm
GraphPad Prism 6.0 GraphPad, La Jolla, CA https://www.graphpad.com/
scientific-software/prism/
Software,
algorithm
Octet Data Analysis
7.0 software
Pall Forte Bio https://shop.fortebio.com/
site-license-octet-data-analysis
-software-version-7.x.html
Materials
[3H]-Diprenorphine (DPN) was from PerkinElmer Life Sciences. BMS-986122 and BMS-986187 (struc-
tures in Figure 5) were synthesized or obtained as previously described (Burford et al., 2013;
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2015). Fentanyl, morphine, methadone and buprenorphine were from the NIDA Drug supply; other
opiates were from the Opioid Basic Research Center at the University of Michigan. All other chemi-
cals, unless otherwise specified, were purchased from Sigma (St. Louis, MO).
Purification of m-OR
Full-length Mus musculus m-OR bearing an amino-terminal FLAG epitope tag and a carboxy-terminal
6xHis tag was expressed in Sf9 insect cells (Invitrogen) using the Best Bacbaculovirus system (Expres-
sion Systems). A tobacco etch virus (TEV) protease recognition sequence was inserted after residue
51 and a rhinovirus 3C protease recognition sequence was inserted before residue 359 for cleavage
during purification. Insect cells were infected with baculovirus encoding m-OR 48–60 hr at 27˚C.
Receptor was solubilized and purified in a final buffer comprised of 25 mM HEPES pH 7.4, 100 mM
NaCl, 0.01% MNG (Anatrace), and 0.001% cholesterol hemisuccinate (CHS), as previously described
(Manglik et al., 2012).
Purification of Nb39
Nb39 was purified as described (Huang et al., 2015). Briefly, Nb39 bearing a carboxy-terminal His
tag was expressed in the periplasm of Escherichia coli strain WK6 grown in Terrific Broth medium
containing 0.1% glucose, 2 mM MgCl2, and 50 mg/ml ampicillin and induced with 0.5 mM isopropyl-
b-D-thiogalactoside (IPTG). Cells were harvested after overnight growth at 25˚C and incubated in a
buffer containing 200 mM Tris, pH 8.0, 0.5 mM EDTA, 500 mM sucrose for one h on ice. Bacteria
were osmotically lysed by rapid dilution in water. The periplasmic fraction was isolated by centrifuga-
tion of cell debris and was supplemented with NaCl (300 mM final) and imidazole (10 mM final).
Nb39 was isolated from the periplasmic fraction by nickel affinity chromatography, and subsequently
purified by size-exclusion chromatography in a buffer comprised of 20 mM HEPES pH7.5 and 100
mM NaCl. Peak fractions were pooled and concentrated to approximately 1 mM.
Apolipoprotein purification and biotinylation
Apolipoprotein-AI (Apo-AI) was purified as described previously (Kuszak et al., 2009). Apo-A1 was
biotinylated using NHS-PEG4-biotin (Pierce Biotechnology) at a 1:1 molar ratio. Following a 30 min
biotinylation reaction at room temperature, the sample was dialyzed to remove free biotin.
Purification and formation of G-protein heterotrimeric complex
Myristoylated Gai1containing a hexahistidine tag inserted at residue 121 (Kozasa and Gilman, 1995)
was expressed in Escherichia coli and purified as described (Greentree and Linder, 2004). To pre-
pare Gbg subunit lacking the geranyl-geranyl modification, Trichoplusiani cells (High Five; Invitrogen)
were infected with baculovirus encoding for Gb1 and His6-Gg2C68S (In˜iguez-Lluhi et al., 1992) at an
MOI of 1 for each virus. Cells were harvested ~48 hr post-infection and lysed by nitrogen cavitation
in a buffer containing 50 mM HEPES (pH 8.0), 65 mM NaCl, 5 mMb-mercaptoethanol (b-ME), and
protease inhibitors (35 mg/ml phenylmethylsulfonyl fluoride, 32 mg/ml each N-tosyl-L-phenylalanine
chloromethyl ketone and N-tosyl-L-lysine chloromethyl ketone, 3.2 mg/ml each leupeptin and soy-
bean trypsin inhibitor). The lysate was centrifuged for 10 min at 1000 g and the resulting supernatant
was centrifuged for 40 min at 100,000 g. The clarified lysate was supplemented with NaCl to a final
concentration of 300 mM and applied to a packed column of cobalt-NTA resin (TALON;Clontech)
pre-equilibrated with wash buffer containing 20 mM HEPES (pH 8.0), 300 mM NaCl, 5 mM b-ME,
and protease inhibitors. The column was washed with 10 column volumes of wash buffer then eluted
with a buffer composed of 20 mM HEPES (pH 8.0), 50 mM NaCl, 150 mM imidazole, 5 mM b-ME,
and protease inhibitors. Fractions were analyzed by SDS-PAGE, and those containing Gbg were
pooled and diluted to a final volume of 50 ml using 20 mM HEPES (pH 8.0), 5 mM b-ME. The diluted
fractions were loaded onto a MonoQ HR 10/10 (GE Life Sciences) pre-equilibrated with 20 mM
HEPES (pH 8.0) and eluted using a linear gradient of NaCl in the same buffer. Fractions containing
Gbg were pooled, concentrated using an Amicon Ultra centrifugal filter, and applied to a Superdex
S200 XK 16/70 (GE Life Sciences). Size exclusion chromatography was performed using a buffer com-
posed of 20 mM HEPES, 100 mM NaCl, 1 mM EDTA, and 100 mM Tris(2-carboxyethyl)phosphine
(TCEP). Peak fractions were pooled and concentrated to ~5 mg/ml as determined by Bradford assay.
Concentrated protein was flash-frozen in liquid nitrogen and stored at  80˚C until use. Complexes
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of myr-Gai1 and Gbg were prepared by mixing the subunits at a 1.2:1 molar ratio in a buffer contain-
ing 20 mM HEPES (pH 8.0), 100 mM NaCl, 1 mM EDTA, 1.1 mM MgCl2, 10 mM GDP, and 100 mM
TCEP. Following a 30 min incubation at 4˚C, complexes were isolated by size exclusion chromatogra-
phy using a Superdex S200 HR 10/30 (GE Life Sciences). Peak fractions were pooled, concentrated
using an Amicon Ultra centrifugal filter, and flash frozen in liquid nitrogen for storage at  80˚C.
m-OR-rHDL Reconstitution
Purified m-OR was reconstituted into high-density lipoprotein (HDL) particles using biotinylated Apo-
AI and the lipids 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) and 1-palmitoyl-2-oleoyl-
sn-glycero-3-phosphoglycerol (POPG) (both from Avanti Polar Lipids) in a 3:2 molar ratio as previ-
ously described (Whorton et al., 2007). For OctetRedÒ experiments, rHDL particles containing
receptor were separated from empty rHDL by anti-FLAG affinity chromotography and elution frac-
tions positive for 3H-diprenorphine binding were pooled.
Nb39 kinetic assays
Nb39 binding to m-OR in the presence or orthosteric and/or allosteric ligands was measured using
the Octet RED biolayer interferometry system (Pall ForteBio). In this assay, m-OR-containing biotiny-
lated rHDL particles are immobilized on a streptavidin-coated fiber optic probe that is incubated
into buffers containing ligands in the presence or absence of Nb39. Different reconstituted receptor
preparations were tested with each ligand to ensure the kinetics did not vary based on the prepara-
tion. Dissociation of bound Nb39 was initiated by placing the probe in buffer containing ligands but
no Nb39. Specifically, biosensors (Pall ForteBio) were loaded with biotinylated m-OR-rHDL particles
for 15 min at room temperature and the biosensors were transferred to the Octet RED instrument.
Sensors were placed into assay buffer (20 mM HEPES, pH 7.7, 100 mM NaCl, 1 mM EDTA, 0.05%
(w/v) BSA) with vehicle or various orthosteric/allosteric ligands for 10 min to reach equilibrium, unless
stated otherwise. To measure Nb39 association, the probe was transferred to assay buffer with
Nb39 (at indicated concentrations) for 5 min, followed by a 10 min dissociation step in assay buffer
(preliminary studies showed that dissociation of Nb39 was quite rapid). All ligands (orthosteric and
allosteric), once introduced to the probe, remained in each subsequent buffer during association
and dissociation. All experiments were carried out at 25˚C with the assay plate shaking at 2000 r.
p.m. Non-specific binding was measured using a vehicle control with no ligands and this was sub-
tracted to account for baseline drift. Raw data were processed to remove baseline using Octet Data
Analysis 7.0 software (Pall Forte Bio) and exported to GraphPad Prism 6.0 for curve fitting of associa-
tion and dissociation using a global linear regression analysis of the families of curves. The number
of independent experiments is listed in the figure legends or tables. No statistical methods were
used to predetermine sample size.
Radioligand binding assays
For competition binding experiments in m-OR- rHDL, a mixture of m-OR-rHDL and 3H-diprenorphine
(3H-DPN) was incubated with varying concentrations of agonist in a binding buffer comprised of 25
mM HEPES pH 7.4, 100 mM NaCl, and 0.1% BSA in the presence or absence of 3 mM Nb39. For
assays performed using cell membranes, conditions listed were kept the same except for exclusion
of BSA and inclusion of 10 mg protein per well. Binding reactions were incubated for 2 h at 25˚C.
Free radioligand was separated from bound radioligand by rapid filtration onto a Whatman GF/C fil-
ter pretreated with 0.1% polyethylenimine using a 24-well harvester (Brandel). Nonspecific binding
was measured in the presence of 10 mM naloxone, an opioid antagonist. Radioligand activity was
measured by liquid scintillation counting using a Wallac 1450 MicroBeta counter (Perkin Elmer). A
minimum of three independent experiments, each in duplicate, were performed and the values were
pooled to generate the mean curves displayed in the figures. Competition binding data were fit to a
one-site model using GraphPad Prism 6.0. Data are presented as means with 95% confidence limits
in parentheses. No statistical methods were used to predetermine sample size.
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